{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:53:13Z","timestamp":1784879593119,"version":"3.55.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00073","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T13:05:23Z","timestamp":1557234323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease"],"prefix":"10.3389","volume":"6","author":[{"given":"Marieke J. H. J.","family":"Dekker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoline C.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"O'Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Makady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pall","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Gispen-de Wied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.52.1.78","article-title":"Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses","volume":"52","author":"Launer","year":"1999","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pharmthera.2011.12.002","article-title":"Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors","volume":"134","author":"Tayeb","year":"2012","journal-title":"Pharmacol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer's disease drug development pipeline: 2017","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B4","unstructured":""},{"key":"B5","unstructured":""},{"key":"B6","unstructured":"De BoerJE PasmanP Procedure Beoordeling Extramurale Geneesmiddelen"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2147\/DDDT.S49935","article-title":"The role of health technology assessment bodies in shaping drug development","volume":"8","author":"Ciani","year":"2014","journal-title":"Drug Des Devel Ther."},{"key":"B8","unstructured":""},{"key":"B9","unstructured":""},{"key":"B10","unstructured":""},{"key":"B11","unstructured":"Donepezil (hydrochloride) (Aspen) bij symptomatische behandeling van licht tot matig ernstige dementie van het Alzheimertype Van der GraaffM"},{"key":"B12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":". Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Arch Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1185\/030079902125001029","article-title":"Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease","volume":"18","author":"Gauthier","year":"2002","journal-title":"Curr Med Res Opin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archneur.57.1.94","article-title":"Donepezil therapy in clinical practice: a randomized crossover study","volume":"57","author":"Greenberg","year":"2000","journal-title":"Arch Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000017259","article-title":"Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease","volume":"11","author":"Homma","year":"2000","journal-title":". Dement Geriatr Cogn Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"Am J Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1468-1331.2006.01409.x","article-title":"Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study","volume":"13","author":"Mazza","year":"2006","journal-title":"Eur J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1378\/chest.07-1446","article-title":"Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study","volume":"133","author":"Moraes","year":"2008","journal-title":"Chest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/sleep\/29.2.199","article-title":"The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study","volume":"29","author":"Moraes Wdos","year":"2006","journal-title":"Sleep."},{"key":"B26","first-page":"170","article-title":"Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease","volume":"9","author":"Peng","year":"2005","journal-title":"Chinese J Clin Rehab."},{"key":"B27","first-page":"293","article-title":"The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial","volume":"7","author":"Rogers","year":"1996","journal-title":". Dementia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/156720507781077296","article-title":"Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?","volume":"4","author":"Winstein","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.wad.0000189052.48688.36","article-title":"Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study","volume":"19","author":"Ancoli-Israel","year":"2005","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/135525705X40436","article-title":"Differential effects of rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial","volume":"10","author":"Cumbo","year":"2005","journal-title":"Prim Care Commu Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0167-4943(01)00134-0","article-title":"Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents","volume":"7","author":"Fuschillo","year":"2001","journal-title":"Arch Gerontol Geriatr Suppl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gps.1038","article-title":"A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease","volume":"19","author":"Jones","year":"2004","journal-title":"Int J Geriatr Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr Alzheimer Res."},{"key":"B37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1742-1241.2002.tb11294.x","article-title":"A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease","volume":"56","author":"Wilkinson","year":"2002","journal-title":"Int J Clin Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00002512-200724020-00007","article-title":"Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis","volume":"24","author":"Hansen","year":"2007","journal-title":"Drugs Aging."},{"key":"B39","unstructured":"Cholinesterase inhibitors in Alzheimer's disease"},{"key":"B40","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin Interv Aging."},{"key":"B41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","article-title":"A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease","volume":"20","author":"Wilcock","year":"2003","journal-title":"Drugs Aging."},{"key":"B42","first-page":"S26","article-title":"Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease","volume":"1","author":"Schneider","year":"1998","journal-title":"Int J Geriatric Psychopharmacol."},{"key":"B43","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately sever Alzheimer's disease","volume":"1","author":"Corey-Bloom","year":"1998","journal-title":"Int J Geriatric Psychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2006.099424","article-title":"Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease","volume":"78","author":"Feldman","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0011-393X(98)85048-0","article-title":"Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type","volume":"59","author":"Agid","year":"1998","journal-title":"Curr Ther Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1468-1331.1999.640423.x","article-title":"A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon)","volume":"6","author":"Forette","year":"1999","journal-title":"Eur J Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/jcp.0b013e31814b98c1","article-title":"Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia?","volume":"27","author":"Mowla","year":"2007","journal-title":". J Clin Psychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease\u2013rivastigmine patch versus capsule","volume":"22","author":"Winblad","year":"2007","journal-title":"Int J Geriatr Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191","article-title":"Rivastigmine for Alzheimer's disease","author":"Birks","year":"2000","journal-title":"Cochrane Database Syst Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. galantamine international-1 study group","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ."},{"key":"B52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":". Neurology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. the galantamine USA-10 study group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int J Geriatr Psychiatry."},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","article-title":"Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease","volume":"161","author":"Cummings","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1503\/cmaj.051432","article-title":"Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial","volume":"174","author":"Rockwood","year":"2006","journal-title":"CMAJ."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747","article-title":"Galantamine for Alzheimer's disease","author":"Olin","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"B62","article-title":"Guidance on the use of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease","year":""},{"key":"B63","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","article-title":"Memantine in severe dementia: results of the 9M-best study (Benefit and efficacy in severely demented patients during treatment with memantine)","volume":"14","author":"Winblad","year":"1999","journal-title":"Int J Geriatr Psychiatry."},{"key":"B65","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","article-title":"A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)","volume":"17","author":"Wilcock","year":"2002","journal-title":"Int Clin Psychopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","article-title":"Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)","volume":"33","author":"Orgogozo","year":"2002","journal-title":"Stroke."},{"key":"B67","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","article-title":"a 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease","volume":"21","author":"van Dyck","year":"2007","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA."},{"key":"B69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000079833","article-title":"Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease","volume":"18","author":"Doody","year":"2004","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/gps.1112","article-title":"Memantine enhances autonomy in moderate to severe Alzheimer's disease","volume":"19","author":"Rive","year":"2004","journal-title":"Int J Geriatr Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine treatment in patients with mild to moderate Alzheime's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr Alzheimer Res."},{"key":"B72","unstructured":"The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (review of TA11)1: A Systematic Review and Economic Model"},{"key":"B73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S026646230200034X","article-title":"Clinical and cost-effectiveness of donepezil, of donepezil, rivastigmine and galantamine for Alzheimer's disease","volume":"18","author":"Clegg","year":"2002","journal-title":"Int JTechnol Assess Health Care"},{"key":"B74","unstructured":"Guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease"},{"key":"B75","unstructured":"Guideline on good pharmacovigilance practices (GVP)"},{"key":"B76","unstructured":""},{"key":"B77","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building synergy between regulatory and HTA agencies beyond processes and procedures-can we effectively align the evidentiary requirements?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health."},{"key":"B78","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fphar.2017.00384","article-title":"A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment?","volume":"8","author":"Allen","year":"2017","journal-title":"Front Pharmacol"},{"key":"B79","unstructured":""},{"key":"B80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21552\/eplr\/2018\/2\/6","article-title":"The danish medicines council: a new prioritisation organ for medicine use in hospitals","volume":"2","author":"Havermann","year":"2018","journal-title":"Eur Pharm Law Review."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00073\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T09:24:17Z","timestamp":1694856257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00073\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":80,"alternative-id":["10.3389\/fmed.2019.00073"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00073","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"article-number":"73"}}